Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
PD-L1 expression
Cancer:
Squamous Cell Carcinoma of Head and Neck
Drug:
Imfinzi (durvalumab)
(
PD-L1 inhibitor
) +
Imjudo (tremelimumab)
(
CTLA4 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Source:
clinicaltrials.gov
Title:
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer
Excerpt:
Subject eligibility will be based on PD-L1 expression as determined by a specified IHC assay.
Trial ID:
NCT02262741
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login